Meeting
2023 ASCO Annual Meeting
Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.
Authors
Jingyi Liu
Brigham and Women's Hospital, Boston, MA
Jingyi Liu , Gowri Jayaram , Tanvee Varma , Stephen Sammut , Carmen Guerra , Jennifer E. Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Health and Regulatory Policy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1594)
DOI
10.1200/JCO.2023.41.16_suppl.1594
Abstract #
1594
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu
Poster
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
First Author: Ademola Samuel Ojo
Poster
2023 ASCO Annual Meeting
Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.
First Author: Maryam Mooghali
Poster
2023 ASCO Annual Meeting
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.
First Author: M. Naomi Horiba